Tirzepatide and Semaglutide have been compared directly, so this question can be answered with more than separate study headlines. In SURMOUNT-5, adults with obesity without diabetes had a greater average weight reduction with Tirzepatide at 72 weeks. The result is relevant, but its population, treatment setting and measured outcome still matter.
For someone in Bali comparing products or discussing a change with a clinician, the next step is to understand what that result does—and does not—answer.
What the direct obesity trial measured
SURMOUNT-5 randomized 751 adults. The reported mean weight changes at week 72 were 20.2% with Tirzepatide and 13.7% with Semaglutide. It was an open-label trial in people with obesity without diabetes. Read the original study abstract.
Those are trial averages for the interventions studied. They should not be presented as a promise attached to every pen that uses either ingredient name.
A comparison also needs more than the most attractive endpoint. Tolerability, discontinuation, medical history and the purpose of treatment belong in an individual clinical decision.
Percentage points and relative differences are different
The difference between 20.2% and 13.7% is 6.5 percentage points. That does not mean every participant lost exactly 6.5% more body weight, and it does not mean a person will lose that much by switching.
Relative statements can sound much larger because they divide the difference by one of the original values. Always ask whether a headline describes percentage points, a relative comparison or a fraction of initial body weight.
This simple reading check prevents a real trial result from being distorted without changing any of the underlying numbers.
Why a diabetes study asks another question
SURPASS-2 compared Tirzepatide with Semaglutide in people with type 2 diabetes. Its main question concerned change in glycated hemoglobin, and its population and treatment regimens differed from SURMOUNT-5. Read the diabetes trial.
| Study question | Relevant distinction |
|---|---|
| Weight change in obesity without diabetes | Read the obesity population and weight endpoint |
| Glucose management in type 2 diabetes | Read the diabetes population and glycemic endpoint |
| Switching an individual treatment | Review clinical history, tolerability and the exact proposed change |
| Choosing a retail pen | Resolve formulation and device identity separately |
Neither trial should be reduced to a universal ranking that ignores why a person is receiving treatment.
Ingredient names and product names are not the same thing
“Tirzepatide” names the molecule. A branded medicine, a particular pen and a catalogue listing contain additional information about preparation and presentation. These details cannot be inferred from the ingredient name alone.
The Peptides in Bali Tirzepatide page describes the available catalogue formats. The Tirzepatide naming guide explains why names such as Mounjaro and Zepbound should not be applied automatically to another pen.
Semaglutide is discussed here as the clinical comparator, not as a claim that it is stocked in this catalogue.
Preparing a comparison for a Bali consultation
If you are already prescribed one medicine, write down the specific reason for considering another. “I saw a larger average in a study” is useful background, but it is not the complete reason for changing an individual plan.
Bring the current product, prescription and any relevant experience to the discussion. Explain whether you are temporarily staying in Seminyak or living in Bali longer term, because follow-up needs to remain workable after the decision.
Ask how the clinician would assess success, tolerability and continuity. A treatment that is being reviewed properly is more than the initial product selection.
The product guide can help locate catalogue information. It does not determine medical suitability or provide a dose-equivalence chart.
Frequently asked questions
Does SURMOUNT-5 mean Tirzepatide is best for everyone?
No. It establishes an average comparison in a defined trial population. Individual treatment decisions require more information.
Can I use the reported percentages as a personal target?
They describe study groups, not a promised target for an individual or a retail product.
Does the study tell me how to switch?
This article does not provide a switching protocol. The responsible clinician needs the current treatment and full clinical context.
Why mention Bali if the trial was not a Bali study?
The clinical evidence is international. The Bali relevance is the practical product and follow-up decision while living or staying here; the trial should not be presented as local research.
Sources and further reading
- Tirzepatide Compared with Semaglutide for Obesity — Aronne et al., NEJM. Source checked 2026-10-19.
- Tirzepatide versus Semaglutide in Type 2 Diabetes — Frias et al., NEJM. Source checked 2026-10-19.